Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q8WTQ7
UPID:
GRK7_HUMAN
Alternative names:
G protein-coupled receptor kinase 7; G protein-coupled receptor kinase GRK7
Alternative UPACC:
Q8WTQ7
Background:
Rhodopsin kinase GRK7, also known as G protein-coupled receptor kinase 7, plays a pivotal role in the retina. It is crucial for the shutoff of the photoresponse and adaptation to changing light conditions through the phosphorylation of cone opsins, including rhodopsin (RHO).
Therapeutic significance:
Understanding the role of Rhodopsin kinase GRK7 could open doors to potential therapeutic strategies.